Mirxes Given Regulatory Roadmap to Resume Trading After Results Delay

Mirxes Holding Company Limited has received a roadmap from the Hong Kong Stock Exchange to resume trading after a suspension due to delays in its 2025 annual results. The company must conduct an independent forensic investigation into certain transactions, demonstrate management integrity, and rectify internal control deficiencies. Full resumption of trading is contingent on meeting regulatory requirements and restoring market confidence. Mirxes is working with compliance adviser Somerley Capital Limited during this period. The company is listed on the Hong Kong Stock Exchange and focuses on compliance in financial reporting and corporate governance.